- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05401695
The Role of Blood Purification by Hemoadsorption as Adjunctive Treatment in Children With Septic Shock
Sepsis is a major healthcare problem and leading cause of death in the pediatric population. Despite advances in supportive care of critically ill patients, sepsis remains an important cause of death worldwide in children. Overall, sepsis incidence peaked in early childhood. There were an estimated 20.3 million incident sepsis cases worldwide among children younger than 5 years. The Surviving Sepsis Campaign (SSC), which standardized the evidence-base approach to management of septic shock and other sepsis-associated organ dysfunction in children, was recently updated. Nevertheless, mortality and costs are still high.
Sepsis is characterized by a complex systemic inflammatory response to a microbial pathogen. A dysregulated host response to infection may result in life-threatening multi-organ dysfunction. Endotoxin, which is found in the outer membrane of Gram-negative bacteria, plays an important role in the pathogenesis of septic shock by producing proinflammatory cytokines. High levels of endotoxin and proinflammatory cytokines are associated with a high mortality rate.
Treatment strategies in sepsis and septic shock include early and adequate fluid resuscitation, vasopressors and inotropic support when indicated, early use of broad-spectrum antibiotics with source control, with close monitoring and organ support, if indicated. Other therapies such as immune-modulation and blood purification have been tried to improve outcomes in patients with sepsis and septic shock. Immunomodulation and blood purification techniques aim at restoring the balance of the immune response to infection, by removing the triggers for the response and the cytokines produced and thereby achieve immune homeostasis. Removing endotoxin and inflammatory cytokines would be an effective adjunctive approach in the management of severe sepsis.
Direct hemoadsorption (HA) is an extracorporeal technique utilized for blood purification. It involves the passage of blood through an adsorption cartridge, where solutes are removed by direct binding to the sorbent material. Over the years, new adsorption cartridge, with improved characteristics have been developed. Resin-directed hemoadsorption is associated with improved oxygenation, hemodynamic status and cardiac function. However, most studies include only adults, and little information is available regarding the clinical experience and efficacy of blood purification for pediatric septic shock.
This pilot study aimed to evaluate the overall clinical outcomes among children who received direct hemoadsorption as an adjunctive treatment for refractory septic shock with high severity scores, compared with outcomes among children admitted to the PICU who received standard treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design This pilot study is the prospective interventional cohort study with comparison to a historical control group at a nine-bed PICU at a university referral hospital. Children with septic shock who meet the inclusion criteria will be enrolled. The HA-treated group will be enrolled between July 2021 and May 2022. The historical control group was composed of patients treated between May 2019 and May 2021. Baseline clinical severity scores were matched between the two groups. Investigators will obtained informed consent from the families of all patients. The confounding factor was controlled by matching ratio 1:3 (baseline clinical severity score matching). So sample size of intervention (HA) group was calculate about 10 cases.
Patients The HA group included children with sepsis, as defined by the Surviving Sepsis Campaign guideline 2020, who were admitted to our PICU during the study period. All children initially received routine treatment for septic shock, including intravenous fluid resuscitation, antibiotics, removal of source of infection and inotropic drugs within 6 hours after the diagnosis of sepsis. Patients were included if they: 1) are 30 days to 15 years of age, 2) require any dose of at least one vasopressor and 3) has a Pediatric Logistic Organ Dysfunction (PELOD)-2 score ≥ 10 or Pediatric Risk of Mortality (PRISM)-3 score ≥ 15. Patients receiving end-of-life support, those with uncontrolled bleeding were excluded. The historical control group included patients with sepsis who were admitted to our PICU with the same inclusion criteria and received standard treatment. Patients will be matched according to baseline clinical severity score.
Hemoadsorption (HA) treatment An HA330 disposable hemoperfusion cartridge (HA330; Jafron, Zhuhai City, China) was used with a continuous renal replacement therapy (CRRT) machine (Aquarius® or Primaflex®) in the intervention group. Investigators will select a blood circuit for each machine according to the patient's body weight. For the Aquarius machine, Aqualine S (64-mL blood volume) will be used for body weight < 30 kg and Aqualine (105-mL blood volume) will be used for weight ≥ 30 kg. Four types of blood circuit will be utilized with the Prismaflex machine, including Prismaflex HF20 set (60 mL) for weight < 3-11 kg, Prismaflex M60 set (93 mL) for weight 11-30 kg and Prismaflex M100 set (152 mL) for weight > 30 kg. After rinsing with normal saline solution with heparin, priming the blood circuit and the cartridge with normal saline solution; using 5% albumin or packed red cells (PRC) when the volume of the extracorporeal circuit is more than 10% of the circulatory volume of the patient. If the albumin level is below 3.5 g/dL and hematocrit is above 30%, 5% albumin will be used for priming. If hematocrit is below 30%, PRC will be used. Vascular access will be established with ultrasound-guided insertion of a double-lumen venous catheter into the right internal jugular or femoral vein. The size of the double-lumen catheter is 8 French (Fr) for patients weighing 6-15 kg, 9-10 Fr for those weighing 15-30 kg and 11.5 Fr for those weighing > 30 kg. HA will be performed for a maximum of 4 hours, and the second session will be started approximately 24 hours after the end of the first session. The blood flow rate will be started low and be gradually increased while monitoring real-time blood pressure and vital signs with an arterial-line monitor. After the end of the HA session, CRRT will be continued if required.
Data collection and study endpoints Demographic data, underlying disease and source of infection are extracted from patients' hospital charts. Blood gas data, type of respiratory support, dose of vasopressors and laboratory data will be recorded at baseline, 24 hours, 48 hours and 72 hours. The baseline is define as a time before HA treatment in the intervention group and when patients will be noted to have no response to initial resuscitation in the control group. The severity of organ dysfunction or failure will be expressed with the PELOD-2 score and PRISM-3 score and recorded at the four time points above. The dose of vasoactive/vasopressor agents will be expressed as the vasoactive inotropic score (VIS), calculated as: dopamine dose + dobutamine dose + (epinephrine dose × 100) + (norepinephrine dose × 100) + (milrinone dose × 10) + (vasopressin dose × 10,000), with doses expressed as mcg/kg/min for most drugs and as U/kg/min for vasopressin. The primary endpoints are the reduction in PELOD-2 and PRISM-3 scores at 72 hours, with adjustment for baseline between the HA and control groups. The secondary endpoints are the reductions in IL-6, VIS, oxygenation index, serum creatinine, base excess and lactate at 72 hours; length of PICU stay, hospital stay and mechanical ventilation; and 28-day mortality.
Laboratory methods Serum samples are analyzed by Direct Ion Selective Electrode for arterial blood gas analysis, which include the data of arterial lactate, base excess and oxygenation index. Complete blood count (CBC) are analyzed by Chemical dye, Laser scattering, SF Cube, Sheath Fluid and Impedance Method to evaluated white blood cell count (WBC) and platelets. Serum creatinine (Cr) and other blood chemistry are analyzed by Reflotron method. IL-6 is analyzed by Electrochemiluminescence immunoassay (ECLIA).
Data analysis and statistics Data analysis using the median with range (minimum-maximum) or mean ± standard deviation. Investigators will use Student's t-test analysis for continuous variables data and Fisher's exact test for categorical variables data. Within-group analysis of PELOD-2, PRISM-3, oxygenation index, VIS, creatinine, base excess, endotoxin levels and lactate will be performed with paired t-tests; between-group comparisons are performed with analysis of covariance (ANCOVA) at 72 hours, with adjustment for the baseline in each group.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bangkok, Thailand, 10330
- Faculty of Medicine, Chulalongkorn University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Children were 30 days to 15 years of age, who required any dose of at least one vasopressor and one of following
- Pediatric Logistic Organ Dysfunction (PELOD)-2 score ≥ 10
- Pediatric Risk of Mortality (PRISM)-3 score ≥ 15
Exclusion Criteria:
- Patients receiving end-of-life support
- Patients who uncontrolled bleeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: The historical control group
The historical control group was composed of patients treated septic shock between May 2019 and May 2021.
They was received routine treatment for septic shock including intravenous fluid resuscitation, antibiotics, removal of source of infection and inotropic drugs within 6 hours after the diagnosis of sepsis.
|
|
ACTIVE_COMPARATOR: The HA-treated group
The HA-treated group will be enrolled between July 2021 and May 2022.
This group included children with sepsis, who were admitted to our PICU during the study period.
All children initially received routine treatment for septic shock as the historical control group.
An HA330 disposable hemoperfusion cartridge (HA330; Jafron, Zhuhai City, China) was used with a continuous renal replacement therapy (CRRT) machine (Aquarius® or Primaflex®) in this intervention group.
|
Hemoadsorption (HA) treatment An HA330 disposable hemoperfusion cartridge (HA330; Jafron, Zhuhai City, China) was used with a continuous renal replacement therapy (CRRT) machine (Aquarius® or Primaflex®) in the intervention group.
We will select a blood circuit for each machine according to the patient's body weight.
Vascular access will be established with ultrasound-guided insertion of a double-lumen venous catheter into the right internal jugular or femoral vein.
HA will be performed for a maximum of 4 hours, and the second session will be started approximately 24 hours after the end of the first session.
The blood flow rate will be started low and be gradually increased while monitoring real-time blood pressure and vital signs with an arterial-line monitor.
After the end of the HA session, CRRT will be continued if required.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The reduction of PELOD-2 score
Time Frame: At 72 hours after start treatment
|
The PELOD-2 score, Pediatrics Logistic Organ Dysfunction-2 score as a descriptive scoring system for organ dysfunction.
It consists of 10 variables which represent 5 organ dysfunctions.
A higher PELOD-2 score correlates with a higher number of organ failures and mortality rate.
The minimum of PELOD-2 score is zero, which mortality rate is 0.4%.
The higher PELOD-2 score more than 16.8 correlated with mortality rate >60%.
|
At 72 hours after start treatment
|
The reduction of PRISM-3 score
Time Frame: At 72 hours after start treatment
|
The PRISM-3 score, Pediatrics Risk of Mortality-3 score has 17 physiologic variables subdivided into 26 ranges.
Similar to the PELOD-2 score, the higher PRISM-3 score correlates with a higher number of organ failures and mortality rate.
The minimum of PRISM-3 score is zero.
The maximum PELOD-2 score is 76.
|
At 72 hours after start treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The reduction in IL-6
Time Frame: At 72 hours after start treatment
|
At 72 hours after start treatment
|
|
The reduction in VIS at 72 hours
Time Frame: At 72 hours after start treatment
|
Vasoactive inotropic score (VIS)
|
At 72 hours after start treatment
|
The reduction in lactate levels at 72 hours
Time Frame: At 72 hours after start treatment
|
At 72 hours after start treatment
|
|
The reduction in oxygenation index at 72 hours
Time Frame: At 72 hours after start treatment
|
At 72 hours after start treatment
|
|
The length of PICU stay
Time Frame: Assessed up to 2 years after PICU admission
|
Assessed up to 2 years after PICU admission
|
|
The length of hospital stay
Time Frame: Assessed up to 2 years after admission in hospital
|
Assessed up to 2 years after admission in hospital
|
|
The length of mechanical ventilation
Time Frame: Assessed up to 2 years after the first intubation in PICU
|
Assessed up to 2 years after the first intubation in PICU
|
|
The 28-day mortality
Time Frame: 28 days from admission
|
28 days from admission
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ped Critical Care KCMH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Septic Shock
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, BonnUnknownSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockGermany
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); The Physicians' Services Incorporated...Recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedSeptic Shock HyperdynamicFrance
-
University Medicine GreifswaldUnknownSepsis Septic ShockGermany
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
University of ZurichCompletedPatients in Septic ShockSwitzerland
-
National Taiwan University HospitalBaxter Healthcare CorporationRecruiting
-
Charite University, Berlin, GermanyCompleted
-
Centre Hospitalier Universitaire DijonCompleted
-
Mansoura UniversityUnknown
Clinical Trials on HA330 hemoadsorption technique
-
Universitätsklinikum Hamburg-EppendorfCytoSorbents Corporation and CytoSorbents Medical Inc.UnknownInflammation | Cardiac Arrest | Resuscitation | Multi-Organ DisorderGermany
-
Centre Hospitalier Universitaire VaudoisCompleted
-
Institutul Clinic FundeniCompleted
-
Sun Yat-sen UniversityCompletedHyperparathyroidism | Insomnia | Refractory Pruritus | OstalgiaChina
-
University of BolognaRecruitingAbdominal Aortic Aneurysm | Endovascular Aortic RepairItaly
-
Escola Superior de Tecnologia da Saúde do PortoNot yet recruiting
-
National Research Center for Cardiac Surgery, KazakhstanMinistry of Education and Science, Republic of KazakhstanRecruitingSepsis | Multiple Organ Failure | Decompensated Heart Failure | Ventricular Arrythmia | Pulmonary Failure | Cardiogenic Shock | Acute Heart Failure | Cardiac Arrest With Successful ResuscitationKazakhstan
-
Universidad Autonoma de Baja CaliforniaCompletedPost Operative PainMexico
-
Natália Maria Oliveira CampeloNot yet recruiting
-
Escola Superior de Tecnologia da Saúde do PortoCompletedLatent Myofascial Trigger Point of Upper Trapezius MusclePortugal